Sol-Gel's IND Application for Rosacea Accepted by FDA

Published: Nov 11, 2009

NESS ZIONA, Israel--(BUSINESS WIRE)--Sol-Gel Technologies announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.

Back to news